Skip to Main Content

H. Frangoul, M.D., M.S., et al. Reni-cel, the first AsCas12a gene-edited cell therapy, shows promising preliminary results in key clinical outcomes in transfusion-dependent beta thalassemia patients treated in the EdiThal trial. Presented at the European Hematology Association (EHA) Annual Congress. June 13-16, 2024.